Fig. 2
From: Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of used PD-L1 antibodies in SD-BLCA according to FDA-approved guidelines for first line therapy in bladder cancer. Scatter plots represent CPS and IC for DAKO 22C3 and Ventana SP142, respectively. Red dotted line: drug-related cut-off values. Below: Percentages of patients with putative choice of first line therapy with pembrolizumab (a) and atezolizumab (b)